Traditionally, it would be assumed that, for example, a BRAF V600E mutation—identified as a known driver of melanoma on the basis that mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells [117]—would be found most abundantly in melanomas rather than in dysplastic or benign nevi. Here, BRAF is linked to melanoma.